Compare Elder Pharma with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs PANACEA BIOTECH - Comparison Results

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA PANACEA BIOTECH ELDER PHARMA/
PANACEA BIOTECH
 
P/E (TTM) x -0.2 11.3 - View Chart
P/BV x 0.1 2.4 4.2% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 ELDER PHARMA   PANACEA BIOTECH
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
PANACEA BIOTECH
Mar-19
ELDER PHARMA/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs380354 107.5%   
Low Rs188138 136.0%   
Sales per share (Unadj.) Rs491.274.6 658.8%  
Earnings per share (Unadj.) Rs-3.26.7 -47.6%  
Cash flow per share (Unadj.) Rs14.415.5 93.0%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs376.557.2 658.1%  
Shares outstanding (eoy) m20.5461.25 33.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.63.3 17.5%   
Avg P/E ratio x-89.336.8 -242.5%  
P/CF ratio (eoy) x19.715.9 124.2%  
Price / Book Value ratio x0.84.3 17.5%  
Dividend payout %00-   
Avg Mkt Cap Rs m5,83315,061 38.7%   
No. of employees `000NA2.3 0.0%   
Total wages/salary Rs m2,1791,471 148.2%   
Avg. sales/employee Rs ThNM1,973.6-  
Avg. wages/employee Rs ThNM635.6-  
Avg. net profit/employee Rs ThNM176.8-  
INCOME DATA
Net Sales Rs m10,0894,567 220.9%  
Other income Rs m25745 572.8%   
Total revenues Rs m10,3464,612 224.3%   
Gross profit Rs m-7922,030 -39.0%  
Depreciation Rs m361540 66.9%   
Interest Rs m2,7561,048 262.9%   
Profit before tax Rs m-3,653486 -751.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,7130-   
Tax Rs m12577 162.3%   
Profit after tax Rs m-65409 -16.0%  
Gross profit margin %-7.844.4 -17.7%  
Effective tax rate %-3.415.9 -21.6%   
Net profit margin %-0.69.0 -7.2%  
BALANCE SHEET DATA
Current assets Rs m9,2402,415 382.7%   
Current liabilities Rs m9,9989,077 110.1%   
Net working cap to sales %-7.5-145.9 5.1%  
Current ratio x0.90.3 347.5%  
Inventory Days Days4665 71.1%  
Debtors Days Days6071 84.5%  
Net fixed assets Rs m10,1248,333 121.5%   
Share capital Rs m20661 335.6%   
"Free" reserves Rs m5,5823,443 162.1%   
Net worth Rs m7,7343,504 220.7%   
Long term debt Rs m4,889461 1,060.1%   
Total assets Rs m22,88213,755 166.4%  
Interest coverage x-0.31.5 -22.2%   
Debt to equity ratio x0.60.1 480.3%  
Sales to assets ratio x0.40.3 132.8%   
Return on assets %11.810.6 111.0%  
Return on equity %-0.811.7 -7.2%  
Return on capital %22.338.7 57.7%  
Exports to sales %3.020.9 14.5%   
Imports to sales %0.48.1 5.2%   
Exports (fob) Rs m307954 32.1%   
Imports (cif) Rs m43372 11.6%   
Fx inflow Rs m3071,203 25.5%   
Fx outflow Rs m125467 26.9%   
Net fx Rs m181736 24.6%   
CASH FLOW
From Operations Rs m11,7541,049 1,120.7%  
From Investments Rs m-561-54 1,047.7%  
From Financial Activity Rs m-6,762-1,011 668.6%  
Net Cashflow Rs m4,432-20 -22,495.9%  

Share Holding

Indian Promoters % 39.6 74.5 53.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.5 0.6 1,250.0%  
FIIs % 16.8 1.3 1,292.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 23.6 153.0%  
Shareholders   16,479 10,259 160.6%  
Pledged promoter(s) holding % 77.6 35.1 221.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   SANOFI INDIA  ABBOTT INDIA  STRIDES PHARMA SCIENCE  CIPLA  TORRENT PHARMA  

Compare ELDER PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 21 Points Higher; Banking and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest during closing hours today and ended their day marginally higher.

Related Views on News

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

PANACEA BIOTECH Announces Quarterly Results (3QFY19); Net Profit Down 137.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

PANACEA BIOTECH Announces Quarterly Results (2QFY19); Net Profit Down 1631.6% (Quarterly Result Update)

Nov 27, 2018 | Updated on Nov 27, 2018

For the quarter ended September 2018, PANACEA BIOTECH has posted a net profit of Rs 975 m (down 1631.6% YoY). Sales on the other hand came in at Rs 1 bn (down 22.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

PANACEA BIOTECH Announces Quarterly Results (4QFY18); Net Profit Down 66.5% (Quarterly Result Update)

Jun 20, 2018 | Updated on Jun 20, 2018

For the quarter ended March 2018, PANACEA BIOTECH has posted a net profit of Rs 86 m (down 66.5% YoY). Sales on the other hand came in at Rs 2 bn (up 0.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Ditch the Risky Fixed Deposits for Safer 'Bluechip Deposits'(Profit Hunter)

Oct 30, 2019

Most people think stocks are riskier than fixed deposits and bonds. The last quarter century proves otherwise.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 8-QTR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS